WallStSmart
RVPH

Reviva Pharmaceuticals Holdings Inc.

NASDAQ: RVPH · HEALTHCARE · BIOTECHNOLOGY

$0.80
+3.19% today

Updated 2026-06-04

Market cap
$5.42M
P/E ratio
P/S ratio
EPS (TTM)
$-3.33
Dividend yield
52W range
$0 – $23
Volume
0.7M

Reviva Pharmaceuticals Holdings Inc. (RVPH) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$724740.00
Gross profit$-724740.00
Gross margin
R&D$946301.00$195744.00$295150.00$4.85M$18.95M$31.42M$22.91M$11.71M
SG&A$175579.00$181116.00$2.14M$5.25M$5.36M$8.08M$7.89M$8.49M
Operating income$-1.12M$-376860.00$-2.43M$-10.10M$-24.31M$-39.50M$-30.80M$-20.20M
Operating margin
EBITDA$-1.12M$-376014.00$-2.33M$-8.52M$-24.11M$-39.21M$-29.88M$-19.83M
EBITDA margin
EBIT$-1.12M$-376860.00$-2.43M$-10.10M$-24.31M$-78.71M$-60.68M
Interest expense$557675.00$469373.00$1.45M$2414.00$182802.00$33725.00$18497.00$13402.00
Income tax$800.00$800.00$800.00$6004.00$20777.00$16949.00$19514.00
Effective tax rate-0.0%-0.1%-0.0%-0.1%-0.1%-0.0%-0.1%0.0%
Net income$-1.68M$-846832.00$-3.78M$-8.52M$-24.34M$-39.26M$-29.92M$-19.86M
Net income growth (YoY)+49.6%-346.8%-125.2%-185.6%-61.3%+23.8%+33.6%
Profit margin

Frequently asked questions

How much free cash flow does RVPH generate?

RVPH produced $-24.59M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is RVPH's balance sheet healthy?

RVPH holds $14.44M in cash and equivalents against — in long-term debt, on $8.65M of shareholder equity. That debt is best read against the cash flow the business throws off each year.